Microcarriers Based on Glycosaminoglycan-Like Marine Exopolysaccharide for TGF-β1 Long-Term Protection.
Alteromonas
/ chemistry
Biological Availability
Cartilage, Articular
/ drug effects
Cell Line
Delayed-Action Preparations
/ administration & dosage
Drug Carriers
/ chemistry
Drug Compounding
/ methods
Drug Implants
Drug Liberation
Humans
Hydrothermal Vents
/ microbiology
Microfluidics
Polysaccharides
/ chemistry
Regeneration
/ drug effects
Tissue Scaffolds
/ chemistry
Transforming Growth Factor beta1
/ administration & dosage
bioactivity
exopolysaccharide
growth factor
microfluidics
microparticles
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
19 Jan 2019
19 Jan 2019
Historique:
received:
19
12
2018
revised:
10
01
2019
accepted:
18
01
2019
entrez:
24
1
2019
pubmed:
24
1
2019
medline:
30
4
2019
Statut:
epublish
Résumé
Articular cartilage is an avascular, non-innervated connective tissue with limited ability to regenerate. Articular degenerative processes arising from trauma, inflammation or due to aging are thus irreversible and may induce the loss of the joint function. To repair cartilaginous defects, tissue engineering approaches are under intense development. Association of cells and signalling proteins, such as growth factors, with biocompatible hydrogel matrix may lead to the regeneration of the healthy tissue. One current strategy to enhance both growth factor bioactivity and bioavailability is based on the delivery of these signalling proteins in microcarriers. In this context, the aim of the present study was to develop microcarriers by encapsulating Transforming Growth Factor-β1 (TGF-β1) into microparticles based on marine exopolysaccharide (EPS), namely GY785 EPS, for further applications in cartilage engineering. Using a capillary microfluidic approach, two microcarriers were prepared. The growth factor was either encapsulated directly within the microparticles based on slightly sulphated derivative or complexed firstly with the highly sulphated derivative before being incorporated within the microparticles. TGF-β1 release, studied under in vitro model conditions, revealed that the majority of the growth factor was retained inside the microparticles. Bioactivity of released TGF-β1 was particularly enhanced in the presence of highly sulphated derivative. It comes out from this study that GY785 EPS based microcarriers may constitute TGF-β1 reservoirs spatially retaining the growth factor for a variety of tissue engineering applications and in particular cartilage regeneration, where the growth factor needs to remain in the target location long enough to induce robust regenerative responses.
Identifiants
pubmed: 30669426
pii: md17010065
doi: 10.3390/md17010065
pmc: PMC6356637
pii:
doi:
Substances chimiques
Delayed-Action Preparations
0
Drug Carriers
0
Drug Implants
0
GY785 DR
0
GY785 DRS
0
Polysaccharides
0
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-17-CE08-0001
Organisme : RFI BIOREGATE
ID : µEncapEPS
Organisme : Fondation de l'Avenir pour la Recherche Médicale Appliquée
ID : BO-RMA-15-001
Références
N Engl J Med. 2001 Feb 1;344(5):385-6
pubmed: 11195802
Osteoarthritis Cartilage. 2002 Mar;10(3):199-206
pubmed: 11869080
Cell Res. 2002 Mar;12(1):19-32
pubmed: 11942407
Biochem J. 1975 Dec;151(3):491-5
pubmed: 1218089
Matrix Biol. 2003 Apr;22(2):101-7
pubmed: 12782137
Nature. 2003 Oct 9;425(6958):577-84
pubmed: 14534577
Adv Drug Deliv Rev. 2003 Nov 28;55(12):1569-93
pubmed: 14623402
J Microsc. 2003 Dec;212(Pt 3):217-38
pubmed: 14629548
Biomaterials. 2004 Aug;25(18):4163-73
pubmed: 15046906
Carbohydr Res. 2004 Oct 4;339(14):2371-80
pubmed: 15388352
Int J Biochem Cell Biol. 2008;40(5):815-20
pubmed: 18295530
Biomaterials. 2008 Aug;29(22):3260-8
pubmed: 18462788
Chem Biol Drug Des. 2008 Dec;72(6):455-82
pubmed: 19090915
Curr Stem Cell Res Ther. 2009 Dec;4(4):318-29
pubmed: 19804369
Cell. 1991 Mar 8;64(5):867-9
pubmed: 2001586
Biomaterials. 2010 Aug;31(24):6279-308
pubmed: 20493521
J R Soc Interface. 2011 Feb 6;8(55):153-70
pubmed: 20719768
Biomaterials. 2011 Sep;32(27):6425-34
pubmed: 21652067
Biomaterials. 2012 Jan;33(3):751-61
pubmed: 22019120
Curr Stem Cell Res Ther. 2012 Mar;7(2):103-9
pubmed: 22023629
Stem Cells. 2012 Mar;30(3):471-80
pubmed: 22131189
Biomicrofluidics. 2012 Jun;6(2):26502-265029
pubmed: 22670170
Acta Biomater. 2013 Dec;9(12):9343-50
pubmed: 23891740
Biomacromolecules. 2014 May 12;15(5):1568-78
pubmed: 24673589
Biomaterials. 2014 Aug;35(25):7228-38
pubmed: 24881028
Nat Rev Rheumatol. 2015 Jan;11(1):21-34
pubmed: 25247412
Carbohydr Polym. 2015 Feb 13;116:189-99
pubmed: 25458289
Osteoarthritis Cartilage. 2015 Mar;23(3):334-50
pubmed: 25534362
Biomed Res Int. 2015;2015:508656
pubmed: 26090416
Adv Drug Deliv Rev. 2015 Nov 1;94:63-76
pubmed: 26325686
J Biomed Mater Res B Appl Biomater. 2017 Feb;105(2):272-282
pubmed: 26478568
Nano Lett. 2016 Feb 10;16(2):883-8
pubmed: 26745552
Carbohydr Polym. 2016 May 20;142:213-21
pubmed: 26917393
Stem Cell Res Ther. 2016 Apr 18;7(1):56
pubmed: 27089917
Drug Deliv. 2017 Nov;24(1):999-1010
pubmed: 28645219
Carbohydr Polym. 2018 Dec 15;202:56-63
pubmed: 30287036
J Appl Microbiol. 1997 Apr;82(4):422-30
pubmed: 9134716
Exp Cell Res. 1998 Jan 10;238(1):265-72
pubmed: 9457080
Tissue Eng. 1998 Winter;4(4):415-28
pubmed: 9916173